Sharekhan has given Buy recommendation for Gland Pharma with a target price of Rs. 4100 in its research report issued on Jul 05, 2021
Sharekhan’s research report on Gland Pharma
Gland’s core markets segment is on a strong footing to grow, backed by an expected double-digit growth in the US markets. Emerging Prospects in China markets and opportunities from the Vaccine arrangement are the key growth drivers. Strong domain expertise and growth prospects, a sturdy earnings track record and strong financials are the key positives for Gland, earnings are expected to stage a strong 39% CAGR over FY2021-FY2023E.
Outlook
We retain a Buy recommendation on Gland Pharma (Gland) with a revised PT of Rs 4,100.